Data-driven healthcare policy discussions are gaining traction after the Covid-19 outbreak and ahead of the 2020 US presidential elections. The US has a hybrid healthcare structure; it is a system that does not provide universal coverage, albeit few years ago enacted a mandate (Affordable Care Act-ACA) that provides coverage for the majority of Americans. The US has the highest health expenditure per capita of all western and developed countries; however, most Americans don’t tap into the benefits of preventive healthcare. It is estimated that only 8% of Americans undergo routine preventive screenings. On a national level, very few states (15 out of the 50) have above-average preventive healthcare metrics. In literature, many studies focus on the cure of diseases (research areas such as drug discovery and disease prediction); whilst a minority have examined data-driven preventive measures—a matter that Americans and policy makers ought to place at the forefront of national issues. In this work, we present solutions for preventive practices and policies through Machine Learning (ML) methods. ML is morally neutral, it depends on the data that train the models; in this work, we make the case that Big Data is an imperative paradigm for healthcare. We examine disparities in clinical data for US patients by developing correlation and imputation methods for data completeness. Non-conventional patterns are identified. The data lifecycle followed is methodical and deliberate; 1000+ clinical, demographical, and laboratory variables are collected from the Centers for Disease Control and Prevention (CDC). Multiple statistical models are deployed (Pearson correlations, Cramer’s V, MICE, and ANOVA). Other unsupervised ML models are also examined (K-modes and K-prototypes for clustering). Through the results presented in the paper, pointers to preventive chronic disease tests are presented, and the models are tested and evaluated.
Despite a number of reports in the literature on the role of epigenetic mechanisms in periodontal disease, a thorough assessment of the published studies is warranted to better comprehend the evidence on the relationship between epigenetic changes and periodontal disease and its treatment. Therefore, the aim of this systematic review is to identify and synthesize the evidence for an association between DNA methylation/histone modification and periodontal disease and its treatment in human adults. A systematic search was independently conducted to identify articles meeting the inclusion criteria. DNA methylation and histone modifications associated with periodontal diseases, gene expression, epigenetic changes after periodontal therapy, and the association between epigenetics and clinical parameters were evaluated. Sixteen studies were identified. All included studies examined DNA modifications in relation to periodontitis, and none of the studies examined histone modifications. Substantial variation regarding the reporting of sample sizes and patient characteristics, statistical analyses, and methodology, was found. There was some evidence, albeit inconsistent, for an association between DNA methylation and periodontal disease. IL6, IL6R, IFNG, PTGS2, SOCS1, and TNF were identified as candidate genes that have been assessed for DNA methylation in periodontitis. While several included studies found associations between methylation levels and periodontal disease risk, there is insufficient evidence to support or refute an association between DNA methylation and periodontal disease/therapy in human adults. Further research must be conducted to identify reproducible epigenetic markers and determine the extent to which DNA methylation can be applied as a clinical biomarker.
The study aims were (1) to explore whether “periodontal treatment” consisting of surgical therapy (flap, resective, or regenerative) or scaling and root planing treatment with long‐term periodontal maintenance treatment, is cost‐effective in terms of preventing periodontitis‐attributable tooth extraction and replacement by implant‐supported crowns (“extraction/replacement”); (2) to assess the effect of cigarette smoking on this cost‐effectiveness. Data for this observational retrospective study were collected from dental charts of patients who had received periodontal therapy and at least annual follow‐up visits for >10 years were analyzed by linear regression generalized estimating equations and generalized linear models. Among 399 adults (199 males, 200 females), those with the least mean annual treatment cost experienced the greatest mean annual costs for extraction/replacement, indicating general cost‐effectiveness. Cigarette smoking adversely impacted this cost‐effectiveness, with current heavy smokers experiencing no cost‐effectiveness. Former smokers with Grade C periodontitis benefitted most, whereas smoking did not influence cost‐effectiveness for Grade B periodontitis. Assessed by mean annual costs of “extraction/replacement,” periodontal treatment was cost‐effective, which decreased in a dose–response manner by former and current smoking intensity. Cigarette smoking should be factored into treatment planning and cost‐effective analyses of periodontal treatment. Smoking cessation should be encouraged.